Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance...
Guardado en:
Autores principales: | Zakaria Maat, Kamran Mushtaq, Mohamed A. Yassin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Karger Publishers
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7fb3f050297a4c249b0e5b71cb52312b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors
por: Yi-Hue Kuo, et al.
Publicado: (2021) -
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Radhakrishnan Ramchandren, et al.
Publicado: (2009) -
CHRONIC MYELOID LEUKEMIA - CLINICAL AND IMMUNOLOGICAL PECULIARITIES IN ADULT PATIENTS
por: O. V. Smirnova
Publicado: (2012) -
METABOLIC STATE OF BLOOD LYMPHOCYTES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOID LEUKEMIA
por: O. V. Smirnova, et al.
Publicado: (2014) -
A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience
por: Reema Singh, et al.
Publicado: (2021)